Hereditary angioedema is a rare but serious problem with the immune system that is passed down through families. It causes swelling, particularly of the face and airways, and abdominal cramping.
FDA: 35 innovative new drugs approved in fiscal year 2011 — Report shows quick approvals of safe and effective medicines occur in the United States before other countries – Over the past 12 months, the U.S. Food and Drug Administration approved 35 new medicines for patients, like two new treatments for hepatitis C; a drug for late-stage prostate cancer; the first new drug for Hodgkin’s lymphoma in 30 years; and the first new drug for lupus in 50 years.
FDA Approves Kalbitor for Treating Potentially Life-Threatening Attacks of Hereditary Angioedema – The U.S. Food and Drug Administration approved Kalbitor (ecallantide) to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE).
ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema – Company Also Granted Expansion of Prophylaxis Therapy Label to Include Patient Labeling for Self-Administration. – ViroPharma Incorporated (Nasdaq: VPHM) announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) related to its supplemental Biologics License Application (sBLA) for Cinryze(TM) (C1 esterase inhibitor [human]) as a treatment for acute attacks of hereditary angioedema (HAE).
